{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
icosapent ethyl
to a specific field?
Status:
Investigational
Source:
NCT02717741: Phase 1 Interventional Unknown status Neoplasms
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
SIM-010603 (Tafetinib) is a structurally novel, oral, multi-targeted receptor tyrosine kinase inhibitor. SIM-010603 inhibited stem cell factor receptor (Kit), vascular endothelial growth factor receptor-2 (VEGFR-2), platelet-derived growth factor receptor-β (PDGFR-β), glial cell line-derived neurotrophic factor receptor (Rearranged during Transfection; RET), and Fms-like tyrosine kinase-3 (FLT3) with IC(50) values between 5.0 and 68.1 nmol/l. SIM010603 inhibited the phosphorylation of PDGFR-β and VEGFR-2. Moreover, SIM-010603 inhibited endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis. SIM-010603 inhibited tumor growth in these xenograft tumor growth models. SIM010603 reduced tumor MVD in T241-VEGF-A tumor xenograft models and decreased positive signals of CD31, NG2 in MDA-MB-435, and LLC-SW-44 xenograft tumor models. SIM-010603 was in development by Simcere Pharmaceutical Group for the cancer treatment. It was in phase I clinical trials by Simcere, Jilin Boda Pharma and Nanjing Yoko Biological Pharma for the treatment of solid tumours, but this research was discontinued.
Status:
Investigational
Source:
INN:nedemelteon [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02542787: Phase 2 Interventional Completed Spasticity in People With Multiple Sclerosis
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Status:
Investigational
Source:
NCT00150397: Phase 2 Interventional Completed Asthma
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Tofimilast is a potent phosphodiesterase-4 (PDE4) inhibitor with low oral bioavailability and no emesis-associated behaviors in ferrets at plasma concentrations up to 152 ng/ml. Tofimilast exhibited an apparent slower absorption through the rat lung after administration as a dry powder, although absorption half-life values were <1 h and therefore the significance of a formulation effect for this compound is questionable. Tofimilast was tested as a therapeutic agent against asthma and chronic obstructive pulmonary disease but development has been discontinued due to lack of efficacy.
Status:
Investigational
Source:
INN:zelnecirnon [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00635804: Phase 1 Interventional Completed Hepatitis C
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
MK-3281 is a potent and orally bioavailable inhibitor of HCV NS5B polymerase which combined excellent cell-based potency with good pharmacokinetic properties in preclinical species. MK-3281 was efficacious in the chimeric mouse model of HCV infection.
Status:
Investigational
Source:
NCT03043482: Phase 1 Interventional Completed Chronic-kidney Disease Stage 5D on Stable Hemodialysis
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04413617: Phase 2 Interventional Completed Rheumatoid Arthritis
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01461083: Phase 1 Interventional Completed Parkinson Disease
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT04022785: Phase 1 Interventional Completed Acute Myeloid Leukemia
(2019)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
